Search

Your search keyword '"Kühl, Anja A"' showing total 864 results

Search Constraints

Start Over You searched for: Author "Kühl, Anja A" Remove constraint Author: "Kühl, Anja A"
864 results on '"Kühl, Anja A"'

Search Results

4. Engineering Therapeutic Regulatory T Cells to Overexpress G Protein-Coupled Receptor 15 Improves Functional Fitness for In Vivo Gut Homing

5. Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7–Blocking Therapy in Inflammatory Bowel Disease

6. TIFA renders intestinal epithelial cells responsive to microbial ADP-heptose and drives colonic inflammation in mice

9. Non-redundant functions of group 2 innate lymphoid cells

10. Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease.

12. A Notch/STAT3-driven Blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in Crohn´s disease patients

16. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells

19. Severe Acute Respiratory Syndrome Coronavirus 2 Attachment Receptor Angiotensin-Converting Enzyme 2 Is Decreased in Crohn’s Disease and Regulated By Microbial and Inflammatory Signaling

20. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo

22. Alzheimer’s disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.

23. Concurrent Ascaris infection modulates host immunity resulting in impaired control of Salmonella infection in pigs.

24. Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

25. Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

26. Supplementary Figure 9 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

27. Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

28. Supplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

29. Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

30. Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

31. Supplementary Figure 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

32. Supplementary Figure 8 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

33. Supplementary Table 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

34. Supplementary Table 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

35. Supplementary Table 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

36. Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

37. Data from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

38. Supplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

39. Supplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

40. Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

41. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn’s disease

43. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

44. Elimusertib has anti-tumor activity in preclinical patient-derived pediatric solid tumor models

46. ConcurrentAscarisinfection modulates host immunity resulting in impaired control ofSalmonellainfection in pigs

47. Activation of gp130 signaling in T cells drives T H 17-mediated multi-organ autoimmunity

48. Spatial Single Cell Profiling Using Imaging Mass Cytometry: Inflammatory Versus Penetrating Crohn's Disease.

Catalog

Books, media, physical & digital resources